A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
Adolescent
Adult
Aged
Aged, 80 and over
California
/ epidemiology
Carcinoma, Ovarian Epithelial
/ mortality
Female
Guideline Adherence
/ statistics & numerical data
Healthcare Disparities
Hispanic or Latino
/ statistics & numerical data
Hospitals, High-Volume
/ statistics & numerical data
Humans
Logistic Models
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Registries
Retrospective Studies
Survival Rate
White People
/ statistics & numerical data
Young Adult
Journal
Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
11
1
2020
medline:
24
6
2020
entrez:
11
1
2020
Statut:
ppublish
Résumé
To validate the observed/expected ratio for adherence to ovarian cancer treatment guidelines as a risk-adjusted measure of hospital quality care, and to identify patient characteristics associated with disparities in access to high-performing hospitals. This was a retrospective population-based study of stage I-IV invasive epithelial ovarian cancer reported to the California Cancer Registry between 1996 and 2014. A fit logistic regression model, which was risk-adjusted for patient and disease characteristics, was used to calculate the observed/expected ratio for each hospital, stratified by hospital annual case volume. A Cox proportional hazards model was used for survival analyses, and a multivariable logistic regression model was used to identify independent predictors of access to high-performing hospitals. The study population included 30,051 patients who were treated at 426 hospitals: low observed/expected ratio (n=304) 23.5% of cases; intermediate observed/expected ratio (n=92) 57.8% of cases; and high observed/expected ratio (n=30) 18.7% of cases. Hospitals with high observed/expected ratios were significantly more likely to deliver guideline-adherent care (53.3%), compared with hospitals with intermediate (37.8%) and low (27.5%) observed/expected ratios (P<.001). Median disease-specific survival time ranged from 73.0 months for hospitals with high observed/expected ratios to 48.1 months for hospitals with low observed/expected ratios (P<.001). Treatment at a hospital with a high observed/expected ratio was an independent predictor of superior survival compared with hospitals with intermediate (hazard ratio [HR] 1.06, 95% CI 1.01-1.11, P<.05) and low (HR 1.10, 95% CI 1.04-1.16, P<.001) observed/expected ratios. Being of Hispanic ethnicity (odds ratio [OR] 0.85, 95% CI 0.78-0.93, P<.001, compared with white), having Medicare insurance (OR 0.74, 95% CI 0.68-0.81 P<.001, compared with managed care), having a Charlson Comorbidity Index score of 2 or greater (OR 0.91, 95% CI 0.83-0.99, P<.05), and being of lower socioeconomic status (lowest quintile OR 0.41, 95% CI 0.36-0.46, P<.001, compared with highest quintile) were independent negative predictors of access to a hospital with a high observed/expected ratio. Ovarian cancer care at a hospital with a high observed/expected ratio is an independent predictor of improved survival. Barriers to high-performing hospitals disproportionately affect patients according to sociodemographic characteristics. Triage of patients with suspected ovarian cancer according to a performance-based observed/expected ratio hospital classification is a potential mechanism for expanded access to expert care.
Identifiants
pubmed: 31923082
doi: 10.1097/AOG.0000000000003665
pmc: PMC7012338
pii: 00006250-202002000-00012
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
328-339Subventions
Organisme : NIMHD NIH HHS
ID : R01 MD009697
Pays : United States
Références
Gynecol Oncol. 2015 Jul;138(1):121-7
pubmed: 25913132
J Clin Oncol. 2005 Dec 20;23(36):9079-88
pubmed: 16301598
Gynecol Oncol. 2014 May;133(2):142-6
pubmed: 24517876
J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49
pubmed: 23138163
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Gynecol Oncol. 2011 Aug;122(2):319-23
pubmed: 21632099
Eur J Surg Oncol. 2015 Apr;41(4):585-91
pubmed: 25624160
Obstet Gynecol. 2013 Jun;121(6):1226-1234
pubmed: 23812456
Oncology (Williston Park). 1997 Nov;11(11A):95-105
pubmed: 9430180
South Med J. 2018 Jun;111(6):333-341
pubmed: 29863220
Cancer. 2010 Oct 15;116(20):4840-8
pubmed: 20578182
Environ Res. 2017 Jul;156:388-393
pubmed: 28395243
Gynecol Oncol. 2015 Dec;139(3):495-9
pubmed: 26387962
Cancer. 2007 May 15;109(10):2031-42
pubmed: 17420977
Gynecol Oncol. 2013 Oct;131(1):158-62
pubmed: 23872110
Med Care. 2016 Sep;54(9):e55-64
pubmed: 24638121
N Engl J Med. 2011 Jun 2;364(22):2128-37
pubmed: 21631325
Gynecol Oncol. 2008 Nov;111(2):173-8
pubmed: 18823649
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Obstet Gynecol. 2015 Apr;125(4):833-842
pubmed: 25751200
Gynecol Oncol. 2006 Nov;103(2):383-90
pubmed: 17005244
Gynecol Oncol. 2010 Sep;118(3):262-7
pubmed: 20573392
Ann Surg Oncol. 2016 Mar;23(3):989-93
pubmed: 26511267
Am J Obstet Gynecol. 2015 Apr;212(4):468.e1-9
pubmed: 25448522
Gynecol Oncol. 2013 Apr;129(1):258-64
pubmed: 23266352
Cancer. 2009 Sep 15;115(18):4210-7
pubmed: 19536873
Cancer. 1997 Aug 15;80(4):816-26
pubmed: 9264366
J Natl Cancer Inst. 2013 Jun 5;105(11):823-32
pubmed: 23539755
Gynecol Oncol. 2014 Feb;132(2):403-10
pubmed: 24361578
Gynecol Oncol. 2014 Jul;134(1):60-7
pubmed: 24680770
J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209
pubmed: 24142821
Gynecol Oncol. 2016 Aug;142(2):211-6
pubmed: 27238084
Arch Pathol Lab Med. 1997 Nov;121(11):1145-50
pubmed: 9372740
Cancer Causes Control. 2001 Oct;12(8):703-11
pubmed: 11562110
Obstet Gynecol. 2017 Sep;130(3):545-553
pubmed: 28796677
Obstet Gynecol. 2003 Sep;102(3):499-505
pubmed: 12962932
Gynecol Oncol. 2012 Apr;125(1):19-24
pubmed: 22108636
Milbank Mem Fund Q. 1966 Jul;44(3):Suppl:166-206
pubmed: 5338568